GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...
Breo Ellipta, a dual-therapy inhaler combining an ICS and LABA, was similarly found to provide comparable or incremental net health benefits when compared to generic ICS/LABA inhalers. ICER's ...
Having begun working together in December 2015, the partners are now ready to bring to market their custom digital sensor for GSK’s asthma and COPD inhaler, Ellipta. The sensor attaches to the ...
Breo Ellipta, a dual-therapy inhaler combining an ICS and LABA, was similarly found to provide comparable or incremental net health benefits when compared to generic ICS/LABA inhalers. ICER's report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results